S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Forecast, Price & News

$37.85
-0.47 (-1.23%)
(As of 09/22/2023 ET)
Compare
Today's Range
$37.37
$38.00
50-Day Range
$35.49
$40.13
52-Week Range
$22.89
$42.22
Volume
19,780 shs
Average Volume
36,408 shs
Market Capitalization
$1.42 billion
P/E Ratio
66.40
Dividend Yield
N/A
Price Target
$35.00

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.5% Downside
$35.00 Price Target
Short Interest
Bearish
4.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

933rd out of 968 stocks

Pharmaceutical Preparations Industry

432nd out of 445 stocks


TARO stock logo

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TARO Price History

TARO Stock News Headlines

Wall Street Insider Makes Prediction about Hot A.I. Stock
50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.
Wall Street Insider Makes Prediction about Hot A.I. Stock
50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.
Taro Provides Results for Year Ended March 31, 2023
Urticaria Drug Market Business Report [2023-2030]
Oxcarbazepine Market Market Trends By 2030
Urticaria Drug Market Facts and Figures By 2030
See More Headlines
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Company Calendar

Last Earnings
7/26/2023
Today
9/22/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
1,554
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
-7.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$25.44 million
Pretax Margin
4.80%

Debt

Sales & Book Value

Annual Sales
$572.95 million
Cash Flow
$1.71 per share
Book Value
$46.05 per share

Miscellaneous

Free Float
32,398,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
0.60
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Uday V. Baldota (Age 53)
    CEO & Director
  • Mr. William J. Coote (Age 68)
    VP, CFO & Chief Accounting Officer
  • Mr. Itamar Karsenti (Age 51)
    VP & Head of Operations
  • Mr. Avi Avramoff (Age 58)
    VP and Head of R&D
  • Mr. Itzik Baruch (Age 60)
    VP of Technical Services
  • Dr. Roman Kaplan (Age 76)
    VP of Scientific and Technical Compliance Mang.
  • Mr. Erik Zwicker J.D. (Age 43)
    VP, Gen. Counsel & Sec.
  • Mr. Ara Aprahamian (Age 55)
    VP of Sales & Marketing
    Comp: $616.14k
  • Ms. Michele Visosky (Age 57)
    VP & Head of Human Resource
  • Mr. Jayesh Shah (Age 67)
    Head of Procurement













TARO Stock - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings
or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price forecast for 2023?

1 brokers have issued 12 month target prices for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they predict the company's share price to reach $35.00 in the next twelve months. This suggests that the stock has a possible downside of 7.9%.
View analysts price targets for TARO
or view top-rated stocks among Wall Street analysts.

How have TARO shares performed in 2023?

Taro Pharmaceutical Industries' stock was trading at $29.04 at the beginning of the year. Since then, TARO stock has increased by 30.8% and is now trading at $37.99.
View the best growth stocks for 2023 here
.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 398,600 shares, an increase of 82.5% from the August 15th total of 218,400 shares. Based on an average trading volume of 64,200 shares, the short-interest ratio is presently 6.2 days. Currently, 4.9% of the shares of the stock are sold short.
View Taro Pharmaceutical Industries' Short Interest
.

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TARO earnings forecast
.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Wednesday, July, 26th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.09. The firm earned $158.89 million during the quarter, compared to analysts' expectations of $149 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 1.52% and a net margin of 3.72%.

What ETF holds Taro Pharmaceutical Industries' stock ?

ARK Israel Innovative Technology ETF holds 58,404 shares of TARO stock, representing 2.19% of its portfolio.

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (1.71%), Renaissance Technologies LLC (1.58%), BlackRock Inc. (1.55%), Dimensional Fund Advisors LP (1.47%), Acadian Asset Management LLC (0.66%) and Hotchkis & Wiley Capital Management LLC (0.59%).

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $37.99.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.43 billion and generates $572.95 million in revenue each year. The company earns $25.44 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

The company employs 1,554 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -